Gaia Bellomo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gaia Bellomo has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ainhoa Mielgo
University of Liverpool
12 shared publications - Maidinaimu Abudula
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Ashton Street, Liverpool L69 3GE, UK
12 shared publications - Michael C. Schmid
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Ashton Street, Liverpool L69 3GE, UK
12 shared publications - Robert Peter Jones
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool , Liverpool , UK
12 shared publications - Chris Halloran
University of Liverpool, Liverpool, UK
11 shared publications - Lucy Ireland
AstraZeneca 1 Bioscience, Oncology R&D Cambridge, United Kingdom
11 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eaed1296
Multiregional profiling reveals THBS1 - SPP1 monocyte-macrophage axis drives immunosuppression and outcome in colorectal liver metastases
Colorectal cancer (CRC) commonly metastasizes to the liver (CRLM), where it is the leading cause of CRC-related deaths. While immune checkpoint therapies show promise, their effectiveness is limited in CRLM due to the immunosuppressive liver tumor microenvironment (TME). Using multiregional tissue sampling from CRLM patient samples, we identified distinct immune zones within CRLM. Active Granzyme + CD8 + T cells were found in normal liver tissue, while CD8 + T cells in the tumor core were dysfunctional. At the tumor margin, we observed a pre-exhausted immune zone enriched in THBS1 + monocytes and CD47 + CD8 + T cells. Trajectory analysis showed that THBS1 + monocytes differentiate into SPP1 + macrophages, which accumulate in the tumor core and promote immune suppression via TIM-3 and CTLA-4 on exhausted CD8 + T cells. The presence of SPP1 + macrophages correlates with increased T cell exhaustion and poor survival, suggesting them as potential targets to restore antitumor immunity in CRLM.
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eaed1296
Open AccessMultiregional profiling reveals THBS1 - SPP1 monocyte-macrophage axis drives immunosuppression and outcome in colorectal liver metastases
Colorectal cancer (CRC) commonly metastasizes to the liver (CRLM), where it is the leading cause of CRC-related deaths. While immune checkpoint therapies show promise, their effectiveness is limited in CRLM due to the immunosuppressive liver tumor microenvironment (TME). Using multiregional tissue sampling from CRLM patient samples, we identified distinct immune zones within CRLM. Active Granzyme + CD8 + T cells were found in normal liver tissue, while CD8 + T cells in the tumor core were dysfunctional. At the tumor margin, we observed a pre-exhausted immune zone enriched in THBS1 + monocytes and CD47 + CD8 + T cells. Trajectory analysis showed that THBS1 + monocytes differentiate into SPP1 + macrophages, which accumulate in the tumor core and promote immune suppression via TIM-3 and CTLA-4 on exhausted CD8 + T cells. The presence of SPP1 + macrophages correlates with increased T cell exhaustion and poor survival, suggesting them as potential targets to restore antitumor immunity in CRLM.
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease, yet effective treatments to inhibit PDAC metastasis are lacking. The rich PDAC tumor microenvironment plays a major role in disease progression. Macrophages are the most abundant immune cell population in PDAC tumors and can acquire a range of functions that either hinder or promote tumor growth and metastasis. Here, we identified that mesothelin secretion by pancreatic cancer cells co-opts macrophages to support tumor growth and metastasis of cancer cells to the lungs, liver, and lymph nodes. Mechanistically, secretion of high levels of mesothelin by metastatic cancer cells induced the expression of VEGF alpha (VEGFA) and S100A9 in macrophages. Macrophage-derived VEGFA fed back to cancer cells to support tumor growth, and S100A9 increased neutrophil lung infiltration and formation of neutrophil extracellular traps. These results reveal a role for mesothelin in regulating macrophage functions and interaction with neutrophils to support PDAC metastasis.Significance:Mesothelin secretion by cancer cells supports pancreatic cancer metastasis by inducing macrophage secretion of VEGFA and S100A9 to support cancer cell proliferation and survival, recruit neutrophils, and stimulate neutrophil extracellular trap formation.See related commentary by Alewine, p. 513
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease, yet effective treatments to inhibit PDAC metastasis are lacking. The rich PDAC tumor microenvironment plays a major role in disease progression. Macrophages are the most abundant immune cell population in PDAC tumors and can acquire a range of functions that either hinder or promote tumor growth and metastasis. Here, we identified that mesothelin secretion by pancreatic cancer cells co-opts macrophages to support tumor growth and metastasis of cancer cells to the lungs, liver, and lymph nodes. Mechanistically, secretion of high levels of mesothelin by metastatic cancer cells induced the expression of VEGF alpha (VEGFA) and S100A9 in macrophages. Macrophage-derived VEGFA fed back to cancer cells to support tumor growth, and S100A9 increased neutrophil lung infiltration and formation of neutrophil extracellular traps. These results reveal a role for mesothelin in regulating macrophage functions and interaction with neutrophils to support PDAC metastasis.Significance:Mesothelin secretion by cancer cells supports pancreatic cancer metastasis by inducing macrophage secretion of VEGFA and S100A9 to support cancer cell proliferation and survival, recruit neutrophils, and stimulate neutrophil extracellular trap formation.See related commentary by Alewine, p. 513
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Supplementary Tables from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease, yet effective treatments to inhibit PDAC metastasis are lacking. The rich PDAC tumor microenvironment plays a major role in disease progression. Macrophages are the most abundant immune cell population in PDAC tumors and can acquire a range of functions that either hinder or promote tumor growth and metastasis. Here, we identified that mesothelin secretion by pancreatic cancer cells co-opts macrophages to support tumor growth and metastasis of cancer cells to the lungs, liver, and lymph nodes. Mechanistically, secretion of high levels of mesothelin by metastatic cancer cells induced the expression of VEGF alpha (VEGFA) and S100A9 in macrophages. Macrophage-derived VEGFA fed back to cancer cells to support tumor growth, and S100A9 increased neutrophil lung infiltration and formation of neutrophil extracellular traps. These results reveal a role for mesothelin in regulating macrophage functions and interaction with neutrophils to support PDAC metastasis.Significance:Mesothelin secretion by cancer cells supports pancreatic cancer metastasis by inducing macrophage secretion of VEGFA and S100A9 to support cancer cell proliferation and survival, recruit neutrophils, and stimulate neutrophil extracellular trap formation.See related commentary by Alewine, p. 513
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease, yet effective treatments to inhibit PDAC metastasis are lacking. The rich PDAC tumor microenvironment plays a major role in disease progression. Macrophages are the most abundant immune cell population in PDAC tumors and can acquire a range of functions that either hinder or promote tumor growth and metastasis. Here, we identified that mesothelin secretion by pancreatic cancer cells co-opts macrophages to support tumor growth and metastasis of cancer cells to the lungs, liver, and lymph nodes. Mechanistically, secretion of high levels of mesothelin by metastatic cancer cells induced the expression of VEGF alpha (VEGFA) and S100A9 in macrophages. Macrophage-derived VEGFA fed back to cancer cells to support tumor growth, and S100A9 increased neutrophil lung infiltration and formation of neutrophil extracellular traps. These results reveal a role for mesothelin in regulating macrophage functions and interaction with neutrophils to support PDAC metastasis.Significance:Mesothelin secretion by cancer cells supports pancreatic cancer metastasis by inducing macrophage secretion of VEGFA and S100A9 to support cancer cell proliferation and survival, recruit neutrophils, and stimulate neutrophil extracellular trap formation.See related commentary by Alewine, p. 513
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Description of supplementary tables
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
Description of supplementary tables
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
- Open Access
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis
- 15 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis